This Is MS Multiple Sclerosis Knowledge & Support Community

BTG Commences Phase IIa Study Of Pleneva For Multiple Sclerosis - Quick Facts
1/21/2010 2:51 AM ET


(RTTNews) - BTG Plc (BGC.L: News ) said it commenced dosing in a European multicentre Phase IIa study of Pleneva, a novel orally administered compound under development as a potential treatment for multiple sclerosis.

According to the company, the study, in 166 patients with the relapsing-remitting form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week open-label extension. The primary endpoint of the study is a reduction in the number of new T1 gadolinium enhanced lesions on MRI at weeks 12, 16, 20 and 24 when compared to placebo.

http://www.btgplc.com/DevelopmentPipeli ... 00134.html

In a small single-centre, double-blind, placebo-controlled clinical pilot study, an experimental Pleneva™ prototype provided clinical benefits to patients with RRMS, including decreases in both relapse rate and EDSS scores, with additional benefits seen on pain and cognitive endpoints.

Now I'm interested.

The reduction in EDSS score got my attention as well!!! Nice find scoobyjude.

Thanks for the update scooby. I've got it in the pipeline under its old, less catchy name, BGC20-0134.

Do we know if this drug made it or not??? Is it in another phase?? I can see it has been awhile, but I am interested. I'm searching through the forum, but I can't seem to find it... Help if you can.
Thanks!

scoobyjude wrote:BTG Commences Phase IIa Study Of Pleneva For Multiple Sclerosis - Quick Facts
1/21/2010 2:51 AM ET


(RTTNews) - BTG Plc (BGC.L: News ) said it commenced dosing in a European multicentre Phase IIa study of Pleneva, a novel orally administered compound under development as a potential treatment for multiple sclerosis

According to the company, the study, in 166 patients with the relapsing-remitting form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week open-label extension. The primary endpoint of the study is a reduction in the number of new T1 gadolinium enhanced lesions on MRI at weeks 12, 16, 20 and 24 when compared to placebo.

any update ? please

arabia wrote:any update ? please

from the manufacturers web site

BGC20-0134 (Pleneva™) did not meet its primary or secondary endpoints in a six-month double-blind placebo-controlled Phase IIa study in patients with relapsing remitting multiple sclerosis. Data from approximately 65% of patients who have completed an optional six-month open-label study extension will be analysed to determine if any treatment effects are evident at 12 months that were not found after 6 months.